Treatment-related adverse events occurred in @ ( @ % ) of @ patients in the dabrafenib and trametinib group and @ ( @ % ) of @ patients in the dabrafenib only group ; the most common was pyrexia ( @ patients , @ % ) in the dabrafenib and trametinib group , and hyperkeratosis ( @ patients , @ % ) in the dabrafenib only group .